Business Information
The group's principal activity is the research, development, manufacture and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. The group's two commercial products, rituxan(R) (rituximab) and zevalin(R) (ibritumomab tiuxetan) are for use in the treatment of certain b-cell non-hodgkin's lymphomas (b-cell nhls). Rituxan is a genetically engineered, chimeric murine/human monoclonal antibody designed to harness the patient's own immune mechanisms to destroy normal and malignant b cells. Zevalin, the group's radioimmunotherapy product approved for treatment of certain b-cell nhl, delivers targeted immunotherapy by means of injectable radiation to target sites expressing the CD20 antigen, such as lymphatic b-cell tumors. In addition, the group is developing products for the treatment of cancer and various autoimmune and inflammatory diseases, such as rheumatoid arthritis, allergic asthma and allergic rhinitis.
|
|
Name |
Title
|
Email
|
| Bruce Ross | Chmn. | N/A | | Cecil Pickett | Dir., Pres. - Research, Development | N/A | | Michael MacLean | Sr. VP, Chief Accounting Officer, Controller | N/A | | Craig Schneier | Exec. VP - Human Resources, Public Affairs, Corporate Communications | N/A | | Faheem Hasnain | Exec. VP - Oncology Rheumatology Strategic Business | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 2,683,049 | 217,511 | | 2005 | 2,422,500 | 160,711 | | 2004 | 2,211,562 | 25,086
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
